Get the Stockscreener App
148.08
1.39%
-2.09
After Hours:
148.08
Natera Inc stock is traded at $148.08, with a volume of 602.61K.
It is down -1.39% in the last 24 hours and down -0.78% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$150.17
Open:
$150.09
24h Volume:
602.61K
Relative Volume:
0.36
Market Cap:
$20.07B
Revenue:
$1.53B
Net Income/Loss:
$-214.69M
P/E Ratio:
-84.14
EPS:
-1.76
Net Cash Flow:
$-43.68M
1W Performance:
+3.35%
1M Performance:
-0.78%
6M Performance:
+21.03%
1Y Performance:
+63.93%
1-Day Range:
$147.13
$150.09
1-Week Range:
$141.18
$152.66
52-Week Range:
$83.13
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
148.08 | 20.07B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Long Term Trading Analysis for (NTRA) - news.stocktradersdaily.com
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Benzinga
The Blood Test Revolution Driving These Three Stocks - Investor's Business Daily
Press Release Distribution & PR Platform - ACCESS Newswire
Lobbying Update: $140,000 of NATERA INC lobbying was just disclosed - Nasdaq
When will cancer return? Personalized Signatera blood test can find early signs of disease - Austin American-Statesman
Natera (NasdaqGS:NTRA) Climbs 11% in One Week - simplywall.st
Barclays Adjusts Natera (NTRA) Price Target Amid Industry Challe - GuruFocus
Assessing Natera: Insights From 10 Financial Analysts - Benzinga
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit? - Yahoo Finance
Natera price target lowered to $160 from $200 at Barclays - TipRanks
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love - Insider Monkey
3 Reasons NTRA Has Explosive Upside Potential - Yahoo Finance
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
15 Stocks with Buy Ratings that Hedge Funds Love - Insider Monkey
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks - Yahoo Finance
Immuno-Oncology Stocks Weather Market Volatility Despite Strong Q4News and Statistics - IndexBox
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance
Multi-Cancer Early Detection Market Critical Analysis with Expert Opinion| GRAIL, Natera, Elypta - openPR.com
Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 2,562 Shares of Stock - MarketBeat
Natera co-founder Sheena Jonathan sells $826,326 in stock By Investing.com - Investing.com Australia
Natera co-founder Sheena Jonathan sells $826,326 in stock - Investing.com India
Is the Market Bullish or Bearish on Natera? - Benzinga
Natera’s president of clinical diagnostics sells $421,428 in stock By Investing.com - Investing.com South Africa
Natera director Marcus Gail boxer sells $563,100 in stock By Investing.com - Investing.com South Africa
Natera director Marcus Gail boxer sells $563,100 in stock - Investing.com India
Natera’s president of clinical diagnostics sells $421,428 in stock - Investing.com
Natera Inc (NTRA) Shares Up 3.33% on Apr 2 - GuruFocus
Natera CFO Michael Burkes sells $354,603 in stock By Investing.com - Investing.com South Africa
Natera CEO Steven Leonard sells $3.56 million in stock By Investing.com - Investing.com South Africa
Natera’s chief legal officer Daniel Rabinowitz sells $194,326 in stock By Investing.com - Investing.com Australia
Natera CEO Steven Leonard sells $3.56 million in stock - Investing.com Australia
Natera CFO Michael Burkes sells $354,603 in stock - Investing.com
DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 27, 2022 in Natera LawsuitNTRA - Newsfile
Is Natera, Inc. (NASDAQ:NTRA) Trading At A 23% Discount? - simplywall.st
Transforming Colorectal Cancer Management with Tumor-Informed ctDNA Testing - Inside Precision Medicine
Quantbot Technologies LP Makes New $878,000 Investment in Natera, Inc. (NASDAQ:NTRA) - MarketBeat
EFG Asset Management North America Corp. Sells 9,323 Shares of Natera, Inc. (NASDAQ:NTRA) - MarketBeat
Game-Changing Heart Transplant Monitoring Trial Results: 1,100+ Patient Study Could Transform Post-Surgery Care - Stock Titan
Natera’s Busy 2025 Continues - The Healthcare Technology Report.
(PDF) Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel - ResearchGate
Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Natera Investors Get Class Status in Prenatal Screening Lawsuit - Bloomberg Law News
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Natera CFO Michael Burkes sells $115,661 in company stock By Investing.com - Investing.com South Africa
Here’s What Lifted Natera (NTRA) in Q4 and 2024 - MSN
Natera’s president John Fesko sells $116,099 in stock By Investing.com - Investing.com Canada
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Natera’s chief legal officer sells $135,521 in stock By Investing.com - Investing.com Canada
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):